---
title: "Niagen Bioscience Subsidiary Signs Supply Agreement"
description: "Niagen Bioscience's subsidiary, ChromaDex, Inc., has signed a Supply Agreement with W. R. Grace & Co.-Conn for the exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL), effective April 1, 20"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250662732.md"
published_at: "2025-07-29T21:25:13.000Z"
---

# Niagen Bioscience Subsidiary Signs Supply Agreement

> Niagen Bioscience's subsidiary, ChromaDex, Inc., has signed a Supply Agreement with W. R. Grace & Co.-Conn for the exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL), effective April 1, 2025, and lasting until April 30, 2029. The agreement includes automatic renewal provisions and a minimum annual purchase requirement. Analysts rate NAGE stock as a Buy with a $6.00 price target, although technical analysis shows bearish momentum and potential overvaluation concerns. Niagen Bioscience focuses on NRCL production, with a current market cap of $763.3M.

### Elevate Your Investing Strategy:

-   Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Niagen Bioscience ( (NAGE) ) just unveiled an announcement.

On July 25, 2025, ChromaDex, Inc., a subsidiary of Niagen Bioscience, signed a Supply Agreement with W. R. Grace & Co.-Conn, effective April 1, 2025, for the exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL). The agreement, which runs until April 30, 2029, includes provisions for automatic renewal and requires ChromaDex to purchase a minimum quantity of NRCL annually. The agreement also outlines a potential future License Agreement for ChromaDex to manufacture NRCL, though its execution is not guaranteed.

The most recent analyst rating on (NAGE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.

**Spark’s Take on NAGE Stock**

According to Spark, TipRanks’ AI Analyst, NAGE is a Outperform.

Niagen Bioscience’s strong financial performance and positive earnings call sentiment are major strengths, indicating robust growth and profitability. However, technical analysis reveals bearish momentum, and the high P/E ratio suggests potential overvaluation. These factors collectively result in a moderate overall stock score.

To see Spark’s full report on NAGE stock, click here.

**More about Niagen Bioscience**

Niagen Bioscience, Inc. operates in the bioscience industry, focusing on the production and supply of Nicotinamide-beta-Riboside Chloride (NRCL), a compound with potential health benefits.

**Average Trading Volume:** 1,099,087

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** $763.3M

See more data about NAGE stock on TipRanks’ Stock Analysis page.

## Trending Articles:

-   Palantir (PLTR) Stock Rallies After Analyst Cites Unique ‘Growth and Margin’ Model
-   IONQ CEO Says ‘The Era of Quantum Supremacy Is Just Around the Corner’
-   PARA Stock Jumps After FCC Approves Paramount-Skydance Merger

Disclaimer & DisclosureReport an Issue

### Related Stocks

- [NAGE.US - Niagen Bioscience](https://longbridge.com/en/quote/NAGE.US.md)
- [CDXC.US - ChromaDex](https://longbridge.com/en/quote/CDXC.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Niagen Bioscience 获得了关键 NR 专利的完整所有权 | Niagen Bioscience 已经从贝尔法斯特女王大学获得了与 NR 相关的关键专利的完全所有权，增强了其在 NAD+ 行业的知识产权地位。该协议包括结构化付款，并解除过去的义务，为 Niagen 提供了更大的战略灵活性。分析师将 N | [Link](https://longbridge.com/en/news/270503070.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.